-
Mashup Score: 2ASRS: Six Cases of Occlusive Retinal Vasculitis Reported After Injection of Apellis’ GA Drug Syfovre - Eyewire+ - 2 year(s) ago
Rare cases of retinal vasculitis have occurred after the first injection of Apellis Pharamceuticals’ recently approved geographic atrophy drug S
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 0Nicox Estimates Potential Annual Global Net Sales for NCX 470 of Over $300 Million - Eyewire+ - 2 year(s) ago
Nicox SA said it that annual global net sales of NCX 470 could be over $300 million within 8 years of the date of launches in the
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
#Nicox SA said it that annual global net sales of #NCX470 could be over $300 million within 8 years of the date of launches in the U.S. and China. https://t.co/PZIvC0REGX #glaucoma https://t.co/HIEmE9kX67
-
-
Mashup Score: 3Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congress - Eyewire+ - 2 year(s) ago
Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data gene
Source: Eyewire+Categories: Latest HeadlinesTweet-
Nicox presented additional data on NCX 470 at the 10th World #Glaucoma Congress in Rome, Italy. Read more: https://t.co/I9ClixwOMe https://t.co/XGI1iUiewo
-
-
Mashup Score: 2Elios Vision Completes Enrollment in US Pivotal Trial; Expands US Pre-Launch Team - Eyewire+ - 2 year(s) ago
Elios Vision announced it has completed enrollment for its pivotal trial of more than 300 patients with mild to moderate glaucoma treated with th
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@elios_vision announces completion of enrollment for its pivotal trial of 300+ patients w/ mild-moderate #glaucoma treated with the Elios procedure in combination w/ cataract surgery. Elios is an implant-free procedure that uses excimer laser technology. https://t.co/KGrP0dHNvG
-
-
Mashup Score: 2Myra Vision Announces Funding to Advance Calibreye Surgical Treatment for Glaucoma Patients - Eyewire+ - 2 year(s) ago
Myra Vision, which is a Shifamed portfolio company, announced the closing of its $25 million Series B financing to further product deve
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@MyraVision announces closing of its Series B financing to further product development, scale manufacturing capabilities, and support investigation of the company's Calibreye System, for the reduction of IOP for patients with moderate-advanced #glaucoma. https://t.co/oavWSUXV29
-
-
Mashup Score: 1Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy) - Eyewire+ - 2 year(s) ago
Cigna has updated its ‘Glaucoma Surgical Procedure’ policy to cover both ab interno canaloplasty and goniotomy (trabeculotomy) procedures
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@Cigna has updated its 'Glaucoma Surgical Procedure' policy to cover both ab interno #canaloplasty and goniotomy (#trabeculotomy) procedures for the treatment of open-angle #glaucoma, effective June 15, 2023. https://t.co/7ll5AR6rbR https://t.co/tRMygPQNm0
-
-
Mashup Score: 0AI Used to Advance Drug Delivery System for Glaucoma and Other Chronic Diseases - Eyewire+ - 2 year(s) ago
Researchers from Wilmer Eye Institute, Johns Hopkins Medicine say they have used artificial intelligence models and machine-learning algorithms to suc
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
Researchers say they have used #artificialintelligence models & machine-learning algorithms to successfully predict which components of amino acids that make up therapeutic proteins are most likely to safely deliver therapeutic drugs to animal #eyecells. https://t.co/eIjkEyzvhc https://t.co/GbbyWr6Lk4
-
-
Mashup Score: 2Dr. Louis R. Pasquale Winner of the Glaucoma Foundation's 2023 Robert Ritch Award - Eyewire+ - 2 year(s) ago
Louis R. Pasquale, MD, FARVO, has been named the 2023 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excelle
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
Dr. Louis Pasquale is named the 2023 recipient of @TGF_Glaucoma Robert Ritch Award for Innovation & Excellence in Glaucoma. The award recognizes contributions of individuals who've played a significant role in promoting the medicine & science of #glaucoma. https://t.co/GKAEiyNIFO
-
-
Mashup Score: 0Sight Sciences Announces 12-Month Results from the First MIGS Comparative Analysis of Real-World Data (RWD) from the IRIS Registry - Eyewire+ - 2 year(s) ago
Sight Sciences announced the results from a 12-month retrospective sub-analysis of IOP-lowering medication use following the three most commonly
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@SightSciences announced the results from a 12-month retrospective sub-analysis of #IOP-lowering medication use following the three most commonly performed, FDA approved (or cleared) MIGS procedures in patients with mild stage #glaucoma. https://t.co/GQsnPruY9b https://t.co/i3pL61EcYT
-
-
Mashup Score: 0
Glaukos announced it has received the “Day 74” notification from the FDA acknowledging the previously submitted new drug application
Source: Eyewire+Categories: Latest Headlines, OphthalmologyTweet-
.@GlaukosCorp announced it has received the “Day 74” notification from the FDA acknowledging the previously submitted NDA for iDose TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review. https://t.co/wF088vOQxs https://t.co/viApLpt9Dg
-
Rare cases of retinal vasculitis occurred after the first injection of @ApellisPharma’s recently approved #geographicatrophy drug #Syfovre (pegcetacoplan), according to a notification from the ASRS ReST Committee. Concerns sent shares of Apellis crashing. https://t.co/PJ9I9u1sbC https://t.co/IjgTovrqzX